130 related articles for article (PubMed ID: 25611185)
21. Advances in the medical treatment of Cushing's syndrome.
Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
[TBL] [Abstract][Full Text] [Related]
22. Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.
Fleseriu M; Petersenn S
Pituitary; 2015 Apr; 18(2):245-52. PubMed ID: 25560275
[TBL] [Abstract][Full Text] [Related]
23. Cushing's disease: towards precision medicine.
Kaiser UB
Cell Res; 2015 Jun; 25(6):649-50. PubMed ID: 25930709
[TBL] [Abstract][Full Text] [Related]
24. Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease.
Netea-Maier RT; van Lindert EJ; den Heijer M; van der Eerden A; Pieters GF; Sweep CG; Grotenhuis JA; Hermus AR
Eur J Endocrinol; 2006 May; 154(5):675-84. PubMed ID: 16645014
[TBL] [Abstract][Full Text] [Related]
25. Reversible "brain atrophy" in patients with Cushing's disease.
Gnjidić Z; Sajko T; Kudelić N; Malenica M; Vizner B; Vrkljan M; Hat J; Rumboldt Z
Coll Antropol; 2008 Dec; 32(4):1165-70. PubMed ID: 19149224
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Directed Therapeutic Targets in Cushing Disease.
Theodoropoulou M; Reincke M
J Clin Endocrinol Metab; 2019 Mar; 104(3):925-933. PubMed ID: 30535260
[TBL] [Abstract][Full Text] [Related]
27. Medical combination therapies in Cushing's disease.
Vilar L; Naves LA; Machado MC; Bronstein MD
Pituitary; 2015 Apr; 18(2):253-62. PubMed ID: 25647330
[TBL] [Abstract][Full Text] [Related]
28. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
29. Innovative tumour targeting therapeutics in Cushing's disease.
von Selzam V; Theodoropoulou M
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101701. PubMed ID: 36511278
[TBL] [Abstract][Full Text] [Related]
30. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
31. Approach to the postoperative patient with Cushing's disease.
Rutkowski MJ; Breshears JD; Kunwar S; Aghi MK; Blevins LS
Pituitary; 2015 Apr; 18(2):232-7. PubMed ID: 25702104
[TBL] [Abstract][Full Text] [Related]
32. Cushing's disease and dural invasion.
Hueng DY; Ma HI; Chen CM
J Neurosurg; 2012 Jul; 117(1):189-90; author reply 190-1. PubMed ID: 22577750
[No Abstract] [Full Text] [Related]
33. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Thearle MS; Freda PU; Bruce JN; Isaacson SR; Lee Y; Fine RL
Pituitary; 2011 Dec; 14(4):418-24. PubMed ID: 19960369
[TBL] [Abstract][Full Text] [Related]
34. Endoscopic transsphenoidal pituitary surgery: a good and safe primary treatment option for Cushing's disease, even in case of macroadenomas or invasive adenomas.
Wagenmakers MA; Boogaarts HD; Roerink SH; Timmers HJ; Stikkelbroeck NM; Smit JW; van Lindert EJ; Netea-Maier RT; Grotenhuis JA; Hermus AR
Eur J Endocrinol; 2013 Sep; 169(3):329-37. PubMed ID: 23786985
[TBL] [Abstract][Full Text] [Related]
35. Comment on "Non-surgical treatment of hormone-secreting pituitary tumors".
Dobson M; Del Porto L; Maartens NF
J Clin Neurosci; 2010 Sep; 17(9):1220-1. PubMed ID: 20570519
[No Abstract] [Full Text] [Related]
36. Rationale for treatment and therapeutic options in Cushing's disease.
Stewart PM; Petersenn S
Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23 Suppl 1():S15-22. PubMed ID: 20129190
[TBL] [Abstract][Full Text] [Related]
37. Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
Salehi F; Scheithauer BW; Moyes VJ; Drake WM; Syro LV; Manoranjan B; Sharma S; Horvath E; Kovacs K
Endocr Pathol; 2010 Dec; 21(4):227-9. PubMed ID: 21061089
[TBL] [Abstract][Full Text] [Related]
38. Non-uniform response to temozolomide therapy in a pituitary gonadotroph adenoma.
Ersen A; Syro LV; Penagos L; Uribe H; Scheithauer BW; Ortiz LD; Rotondo F; Horvath E; Kovacs K
Can J Neurol Sci; 2012 Sep; 39(5):683-5. PubMed ID: 23066557
[No Abstract] [Full Text] [Related]
39. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
Kreutzer J; Jeske I; Hofmann B; Blumcke I; Fahlbusch R; Buchfelder M; Buslei R
Clin Neuropathol; 2009; 28(6):430-9. PubMed ID: 19919817
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
